Sacituzumab govitecan-hziy
Sacituzumab Govitecan-hziy
Sacituzumab Govitecan-hziy (pronunciation: sah-si-TOO-zoo-mab goh-VIH-teh-kan HZIY) is a monoclonal antibody-drug conjugate used in the treatment of various types of cancer, including triple-negative breast cancer and urothelial cancer.
Etymology
The name "Sacituzumab Govitecan-hziy" is derived from its components. "Sacituzumab" is the monoclonal antibody that targets the Trop-2 protein, which is overexpressed in many types of cancer. "Govitecan" is the topoisomerase inhibitor that is conjugated to the antibody, and "hziy" is a suffix used in the World Health Organization's International Nonproprietary Names for humanized monoclonal antibodies.
Mechanism of Action
Sacituzumab Govitecan-hziy works by binding to the Trop-2 protein on the surface of cancer cells. This allows the drug to be taken up by the cancer cells, where the topoisomerase inhibitor can interfere with the cells' ability to replicate their DNA, leading to cell death.
Related Terms
- Monoclonal antibody
- Drug conjugate
- Cancer
- Triple-negative breast cancer
- Urothelial cancer
- Trop-2
- Topoisomerase inhibitor
- World Health Organization
- International Nonproprietary Names
External links
- Medical encyclopedia article on Sacituzumab govitecan-hziy
- Wikipedia's article - Sacituzumab govitecan-hziy
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski